MorphoSys AG (MOR)
|Net Income (ttm)||26.75M|
|Trading Day||January 26|
|Day's Range||30.39 - 30.77|
|52-Week Range||18.86 - 35.72|
MorphoSys and Incyte Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab
PLANEGG/MUNICH, GERMANY and MONTREAL, QC / ACCESSWIRE / January 12, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced th...
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / January 11, 2021 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR), a commercial-stage biopharmaceutical company and a lead...
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / January 6, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in...
High-Yield equity REITs have regularly underperformed. We expect that trend to continue over the next decadeREITs with high yields, low FFO multiples, and weak balance sheets have regularly un...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / December 17, 2020 / MorphoSys AG: Corporate Calendar 2021 Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2021 as follows: Public...
MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript
MorphoSys AG (MOR) CEO Jean-Paul Kress on Q3 2020 Results - Earnings Call Transcript
Incyte (INCY), Xencor and MorphoSys ink deal to evaluate the combination of tafasitamab, plamotamab and lenalidomide in lymphoma indications.
Xencor, MorphoSys and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab
MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) and Incyte (N...
Incyte and MorphoSys to Host Investor Event to Discuss the Unmet Need and Global Opportunities for Tafasitamab in Non-Hodgkin Lymphomas
Analyst and investor conference call and webcast scheduled for Tuesday, September 29, 2020 at 9:00 a.m. EDT / 3:00 p.m. CEST
MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript
MorphoSys FDA Approval, And Other News: The Good, Bad And Ugly Of Biopharma
Profitability analysis is considered one of the best possible ways to assess the prospects of a company.
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
MorphoSys AG (MPSYF) CEO Jean Kress on Q1 2020 Results - Earnings Call Transcript
The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.
MorphoSys AG (MPSYF) CEO Jean-Paul Kress on Q4 2019 Results - Earnings Call Transcript
MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.
MorphoSys AG's (MOR) CEO Simon Moroney on Q4 2018 Results - Earnings Call Transcript
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatme... [Read more...]
|IPO Date |
Mar 9, 1999
|Stock Exchange |
|Ticker Symbol |
In 2019, MorphoSys's revenue was $71.76 million, a decrease of -6.13% compared to the previous year's $76.44 million. Losses were -$103.01 million, 83.4% more than in 2018.
According to 3 analysts, the average rating for MorphoSys stock is "Buy." The 12-month stock price forecast is 36.70, which is an increase of 19.70% from the latest price.